Tuesday, August 17, 2021 1:08:25 PM
ACTIVE POSITIONS HOLDERS SHARES
Increased Positions 64 5,441,175
Decreased Positions 49 4,990,352
Held Positions 19 111,261,581
Total Institutional Shares 132 121,693,108
https://www.nasdaq.com/market-activity/stocks/lxrx/institutional-holdings
Lexicon Pharmaceuticals (NASDAQ:LXRX) - P/E: 7.72
Lexicon Pharmaceuticals has reported Q2 earnings per share at -0.13, which has increased by 13.33% compared to Q1, which was -0.15.
Cooper Companies has reported Q2 earn
Really nothing to get excited about.
For me, it's about the volatility. It'll be a bit longer for their major catalysts but I'll be keeping a core.
Best to all the lurkers out there!!!
Possibly see $3 even soon.
Increased Positions 64 5,441,175
Decreased Positions 49 4,990,352
Held Positions 19 111,261,581
Total Institutional Shares 132 121,693,108
https://www.nasdaq.com/market-activity/stocks/lxrx/institutional-holdings
Lexicon Pharmaceuticals (NASDAQ:LXRX) - P/E: 7.72
Lexicon Pharmaceuticals has reported Q2 earnings per share at -0.13, which has increased by 13.33% compared to Q1, which was -0.15.
Cooper Companies has reported Q2 earn
Really nothing to get excited about.
For me, it's about the volatility. It'll be a bit longer for their major catalysts but I'll be keeping a core.
Best to all the lurkers out there!!!
Possibly see $3 even soon.
Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
Recent LXRX News
- Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/28/2026 12:30:00 PM
- Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference • GlobeNewswire Inc. • 05/12/2026 12:30:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 05/09/2026 01:42:51 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:21:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:31:57 AM
- Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:01:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:59:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:32:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:20:08 PM
- Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital • GlobeNewswire Inc. • 05/04/2026 08:05:00 PM
- Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 • GlobeNewswire Inc. • 04/30/2026 12:00:00 PM
- Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting • GlobeNewswire Inc. • 04/17/2026 12:00:00 PM
- Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/24/2026 12:00:00 PM
- Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/16/2026 08:05:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/16/2026 08:04:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 08:03:08 PM
- Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes • GlobeNewswire Inc. • 03/11/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 09:50:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 12:01:32 PM
- Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates • GlobeNewswire Inc. • 03/05/2026 11:59:00 AM
- Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences • GlobeNewswire Inc. • 03/03/2026 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 12:20:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 12:20:20 PM
